Yiping Zhang

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i> -Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia et al. · Clinical Cancer Research · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

Ziming Li, Xiaomin Dang, Dingzhi Huang et al. · The Lancet Respiratory Medicine · 2024 · 38 citations

Medicine, Genetics, Oncology +6

Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis

Zhengbo Song, Ling Yang, Zhipeng Zhou et al. · Cell Death and Disease · 2021 · 34 citations · Full text

Medicine, Immunology, Oncology +17

Whole Genome Sequencing of the Blue Tilapia (Oreochromis aureus) Provides a Valuable Genetic Resource for Biomedical Research on Tilapias

Chao Bian, Jia Li, Xueqiang Lin et al. · Marine Drugs · 2019 · 30 citations · Full text

Life Sciences, Biology, Genetics +16

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Shun Lü, Yiping Zhang, Guojun Zhang et al. · Journal of Thoracic Oncology · 2022 · 23 citations · Full text

Medicine, Oncology, Pharmacology +11